Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 2/2004

01-03-2004

Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247

Authors: Kristen E. Shannon, Jeffery L. Keene, Steven L. Settle, Tiffany D. Duffin, Maureen A. Nickols, Marisa Westlin, Sally Schroeter, Peter G. Ruminski, David W. Griggs

Published in: Clinical & Experimental Metastasis | Issue 2/2004

Login to get access
Metadata
Title
Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247
Authors
Kristen E. Shannon
Jeffery L. Keene
Steven L. Settle
Tiffany D. Duffin
Maureen A. Nickols
Marisa Westlin
Sally Schroeter
Peter G. Ruminski
David W. Griggs
Publication date
01-03-2004
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 2/2004
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/B:CLIN.0000024764.93092.5f

Other articles of this Issue 2/2004

Clinical & Experimental Metastasis 2/2004 Go to the issue

OriginalPaper

Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: Role of cyclooxygenase-2

OriginalPaper

Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice

OriginalPaper

Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications

OriginalPaper

A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation

OriginalPaper

Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients

OriginalPaper

Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits